|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.260 USD | +11.88% |
|
-0.88% | -3.00% |
| 06-17 | GSK says US FDA approves urinary tract infection treatment Utebzi | AN |
| 06-17 | GSK plc Receives US FDA Approval for Oral Antibiotic Tebipenem for Complicated Urinary Tract Infections | CI |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | +11.88% | -0.88% | -22.87% | -3.00% | -3.00% | -23.13% | +58.04% | -84.83% | - | 131M | |
| +0.33% | +1.37% | +10.60% | +29.14% | +9.43% | +63.66% | +126.38% | +194.67% | +6,960.31% | 55.63B | |
| +0.82% | +15.05% | +15.15% | +21.84% | +30.38% | +79.52% | +85.53% | -24.53% | - | 52.25B | |
| +1.36% | +0.36% | -1.91% | +6.47% | -4.18% | -14.52% | -13.83% | -60.34% | - | 23.07B | |
| -1.04% | +7.91% | -2.84% | -28.85% | -40.60% | +3.91% | +417.68% | +257.22% | +1,042.32% | 22.41B | |
| -0.18% | +7.20% | -1.90% | +2.10% | +5.09% | +31.37% | -13.62% | -76.78% | - | 17.32B | |
| -1.10% | +4.00% | -1.28% | +1.16% | -16.03% | +29.97% | -33.36% | -34.79% | +57.88% | 15.94B | |
| +2.89% | +5.51% | +9.47% | +31.88% | +24.96% | +25.42% | +186.30% | +133.86% | +635.17% | 13.77B | |
| -3.35% | +8.96% | +31.70% | +80.47% | +145.74% | +134.32% | +289.59% | +1,327.33% | +529.57% | 13.47B | |
| +1.31% | +0.53% | -11.81% | -8.65% | +6.58% | +27.83% | - | - | - | 12.43B | |
| -0.22% | +1.36% | -2.85% | +0.39% | -11.97% | +70.46% | +151.45% | +408.53% | - | 11.82B | |
| +1.72% | +4.33% | +6.53% | +31.50% | +29.35% | +147.86% | +143.53% | +265.29% | +811.20% | 11.16B | |
| -0.48% | -3.58% | -0.13% | +36.54% | +18.83% | +390.61% | +118.65% | -12.66% | +1,434.82% | 11.11B | |
| -1.20% | +1.89% | -19.30% | -15.50% | -19.90% | -31.99% | +451.57% | +109.73% | +81.71% | 10.87B | |
| -2.52% | -4.85% | -27.69% | -34.10% | -26.28% | -9.95% | +138.34% | +31.08% | - | 9.78B | |
| -0.01% | +0.07% | +15.03% | +27.79% | +22.80% | +55.02% | +189.82% | - | - | 9.76B | |
| +11.81% | +18.34% | +10.39% | +18.02% | +339.90% | +222.59% | +232.44% | -39.72% | - | 9.12B | |
| +0.74% | -.--% | -.--% | -.--% | -.--% | -.--% | +37.62% | +246.91% | - | 8.19B | |
| +5.29% | +9.88% | +10.78% | +6.32% | +22.50% | +73.48% | +10.71% | +135.50% | - | 8.16B | |
| -0.57% | +1.68% | -15.37% | -26.02% | -3.26% | +25.38% | +116.64% | -43.79% | - | 7.72B | |
| Average | +1.37% | +3.56% | +0.09% | +8.87% | +26.52% | +65.09% | +141.76% | +151.82% | +1,444.12% | 16.21B | |
| Weighted average by Cap. | +0.58% | +4.38% | +4.31% | +13.21% | +20.76% | +63.90% | +136.31% | +143.45% | +2,936.37% |
- Stock Market
- Stocks
- SPRO Stock
- Sector Spero Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
